|
|
|
|
|
|
|
|
| Hello awha hawhwa, |
|
the Series B financing round of PIUR Imaging has just started. The MedTech company comes from the portfolio of Ascend Capital Partners. The existing shareholders Ascend Capital Partners and Business Angels from the medical industry co-invest EUR 1.25 million in the financing round.
PIUR Imaging enables high-resolution 3D ultrasound images of entire organs for the first time and thus elevates one of the world's most used imaging procedures to a new stage of development. This is based on a portfolio of six patent families, which creates a pronounced technological moat.
With FDA approval, CE certification (MDR Class IIa) and over 150 customers, PIUR is already established in the market. GE Healthcare – the global leading ultrasound manufacturer with around 35% market share – has also already integrated the technology into its own systems in a strategic partnership.
A total of EUR 12.7 million has already been invested by international VCs with a MedTech focus and experienced industry experts, including Ascend Capital Partners and former executives of the medical technology group B. Braun. |
|
|
|
|
|
|
|
|
| INVESTMENT HIGHLIGHTS |
|
|
|
|
| • |
|
Upgrade instead of replacement: PIUR expands existing ultrasound systems vendor-agnostically by the 3rd dimension, instead of forcing new purchases. |
|
|
| • |
|
Clear clinical benefit: Faster scans, automated annotation and documentation, less manual effort, higher reimbursement. |
|
|
| • |
|
High workflow relevance: Higher diagnostic quality, separation of image acquisition and diagnosis for the first time possible. |
|
|
| • |
|
With approval in the market: PIUR has CE certification and FDA approval Scalable AI platform: several major clinical applications, including thyroid and other vascular solutions. |
|
|
| • |
|
Scalable AI platform: Several major clinical applications, including thyroid and other vascular solutions. |
|
|
|
|
|
|
|
|
|
|
|
| What does PIUR IMAGING do? |
|
| PIUR IMAGING transforms conventional ultrasound into a scalable 3D imaging solution: Instead of point-by-point 2D images, an organ is scanned once with the probe, while the software combines the captured data into a complete, three-dimensional volume image. For the first time, this creates large-area 3D representations in real time – regardless of the doctor's experience. This enables standardized and automated diagnostics, reduces examination times and creates the basis for new data-based applications in modern telemedicine. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Companisto GmbH |
|
Köpenicker Str. 154, 10997 Berlin
Managing Director: Tamo Zwinge, LL. M. and David Rhotert
Amtsgericht: Berlin Charlottenburg HRB 132811 B
VAT-ID: DE 276 014 929
Phone: +49 30 330 837 49
Email: service@companisto.com |
|
|
|
|
|
|
|
|
| You receive this newsletter because you have subscribed to it. You can unsubscribe at any time via the unsubscribe link. |
|
| The acquisition of the offered securities and investments is associated with considerable risks and can lead to the complete loss of the invested assets. The expected yield is not guaranteed and may be lower. Whether it is a security or an asset investment can be seen in the description of the investment opportunity. |
|
|
|
|
|
|
